Trials / Completed
CompletedNCT00101569
Aripiprazole Oral Acceptability Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 59 (planned)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14). |
| DRUG | Aripiprazole | Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21). |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-03-01
- Completion
- 2005-03-01
- First posted
- 2005-01-13
- Last updated
- 2013-11-08
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00101569. Inclusion in this directory is not an endorsement.